From Hit to Lead: De Novo Design Based on Virtual Screening Hits of Inhibitors of tRNA-Guanine Transglycosylase, a Putative Target of Shigellosis Therapy
作者:Ruth Brenk、Hans-Dieter Gerber、Jeffrey D. Kittendorf、George A. Garcia、Klaus Reuter、Gerhard Klebe
DOI:10.1002/hlca.200390128
日期:2003.5
Shigellosis, a bacterial disease, causes the death of more than one million people per year. Extensive studies of Shigella flexneri have recognized tRNA-guanine transglycosylase (TGT, EC 2.4.2.29) as one of the key enzymes involved in the regulation of bacterial virulence. Based on the crystal structure of the Zymomonas mobilis enzyme, we have embarked on the rational design of TGT inhibitors. Herein
志贺氏菌病是一种细菌性疾病,每年导致超过100万人死亡。弗氏志贺氏菌的广泛研究已经认识到,tRNA-鸟嘌呤转糖基酶(TGT,EC 2.4.2.29)是参与细菌毒力调节的关键酶之一。基于运动发酵单胞菌(Zymomonas mobilis)酶的晶体结构,我们开始了TGT抑制剂的合理设计。在此,我们描述了以前通过虚拟筛选发现的命中基于结构的优化(请参见表1-3)。对于蝶啶,这是先前虚拟筛选运行中发现的最有效的化合物类别,可以建立通用的合成方法,从而可以使用广泛的取代衍生物(请参阅方案5))。该系列中最好的配体14的K i = 0.45μM。